II. Indications
- FDA Approved (part of combination protocols)
- Non-Small Cell Lung Cancer (non-operative, not amenable to Radiation Therapy)
- Pancreatic Cancer (metastatic)
- Breast Cancer (metastatic, refractory or relapsing)
- Off-Label
- Metastatic Melanoma
- Ovarian Cancer or associated cancers (fallopian tube cancer, primary peritoneal cancer)
III. Contraindications
- Hepatic Impairment (relative contraindication)
- Increased toxicity risk
IV. Mechanism
- See Mitotic Inhibitor Chemotherapy
- Albumin-Bound Paclitaxel is a injection formulation of nanoparticles
- Removes toxicity inducing solvents, improving Paclitaxel safety and Therapeutic Index
-
Paclitaxel is a Taxane antineoplastic agent
- Derived from extract of the Pacific yew tree (Taxus brevifolia)
-
Paclitaxel has antineoplastic activity as a an antitubulin agent
- Binds and stabilizes tubulin
- Inhibits microtubule disassembly
- Results in cell cycle arrest in G2/M phase
- Paclitaxel induces apoptosis
V. Medications
- Protein-Bound Paclitaxel for IV Infusion: 100 mg Vial
VI. Dosing
- See other references for disease specific dosing protocols
VII. Adverse Effects
- Hypersensitivity Reaction
- Myelosuppression (Bone Marrow suppression) with Neutropenia
- Peripheral Neuropathy (sensory)
- Future impaired fertility
- Alopecia
- Cardiac conduction abnormalities
VIII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring
IX. Resources
- Paclitaxel Protein-bound particles for injectable suspension (DailyMed)
- Paclitaxel (StatPearls)